Skip to main content

Table 3 Change in SiSBP, SiDBP, and LDL-C from baseline at week 8

From: A randomized, double-blind, multicenter, phase III study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapy

Variable

Treatment groups

FMS/ALD + RSV

vs. FMS/ALD

FMS/ALD + RSV

vs. FMS + RSV

FMS/ALD + RSVa

(n = 43)

FMS/ALDb

(n = 45)

FMS + RSVc

(n = 43)

LSM difference (SE)

P-valued

LSM difference (SE)

P-valued

SiSBP (mmHg)

 Baseline

153.98 ± 10.29

152.93 ± 8.69

152.52 ± 8.56

    

 Week 8

131.00 ± 13.77

126.94 ± 11.84

141.67 ± 14.18

    

 Change

–22.98 ± 13.65

–25.99 ± 13.87

–10.85 ± 12.24

    

 P-value

< 0.001

< 0.001

 < 0.001

    

ANCOVA result

LSM (SE)

–22.72 ± 1.93

–26.32 ± 1.85

–11.11 ± 1.93

3.68 ± 2.65

0.169

–11.62 ± 2.73

< 0.001

SiDBP (mmHg)

 Baseline

89.71 ± 8.01

90.69 ± 8.61

94.41 ± 7.53

    

 Week 8

78.17 ± 8.68

77.53 ± 6.98

86.31 ± 8.79

    

 Change

–11.54 ± 8.86

–13.16 ± 8.21

–8.10 ± 8.57

    

 P-value

< 0.001

 < 0.001

 < 0.001

    

ANCOVA result

 LSM (SE)

–11.83 ± 1.08

–12.88 ± 1.06

–6.94 ± 1.23

1.05 ± 1.51

0.490

–5.78 ± 1.77

0.002

LDL-C (mg/dL)

 Baseline

157.21 ± 27.45

151.22 ± 32.86

157.95 ± 36.43

    

 Week 8

80.67 ± 32.29

143.58 ± 36.70

77.42 ± 27.26

    

 Percent change

–48.52 ± 18.63

–4.43 ± 18.27

–49.68 ± 18.19

    

 P-value

< 0.001

0.111

< 0.001

    

ANCOVA result

 LSM (SE)

–48.32 ± 2.82

–4.63 ± 2.76

–49.64 ± 2.77

–43.69 ± 3.95

 < 0.001

1.07 ± 3.91

0.785

  1. Data are presented as mean ± standard deviation unless otherwise indicated
  2. SiSBP Sitting systolic blood pressure, SiDBP Sitting diastolic blood pressure, LDL-C Low-density lipoprotein cholesterol, LSM Least square mean, SE Standard error, ANCOVA Analysis of covariance
  3. a FMS/ALD + RSV; Study group, fimasartan 60 mg/amlodipine 10 mg + rosuvastatin 20 mg treatment
  4. b FMS/ALD; Control 1 group, fimasartan 60 mg/amlodipine 10 mg treatment
  5. c FMS + RSV; Control 2 group, fimasartan 60 mg + rosuvastatin 20 mg treatment
  6. d Comparison between treatment was analyzed by ANCOVA model adjusted for factor and baseline values
Back to article page

Clinical Hypertension

ISSN: 2056-5909

Contact us